In the Margins
Hedge-fund billionaire John Paulson has joined the Valeant Pharmaceuticals International board of directors. Paulson has been one of the largest shareholders in the company for several years, but a series of scandals at Valeant over its accounting practices and drug pricing have battered the company’s stock and caused the value of Paulson’s stake to plunge 81% to $245 million at the end of last year from $1.3 billion in 2015. Read the original story from The Wall Street Journal.
Most Read
The JPMorgan Funds board has started off the New Year with new leadership following the retirement on Dec. 31 of Chairman Matthew Goldstein, who served in ...
The end of the decade is just weeks away, and mutual fund boards are looking ahead to 2020 and the issues and challenges that may land ...
The Securities and Exchange Commission should issue valuation guidance for investment companies. When I was chief counsel in the SEC's Division of Investment Management from 1997 ...
When a mutual fund board brings on a new independent director, the onboarding process can be all-encompassing (and many would argue it should be). Obviously, there ...